127 related articles for article (PubMed ID: 1605286)
21. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.
Sulak P; Lippman J; Siu C; Massaro J; Godwin A
Contraception; 1999 Mar; 59(3):161-6. PubMed ID: 10382078
[TBL] [Abstract][Full Text] [Related]
22. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
23. Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol.
Lawson JS; Yuliano SE; Pasquale SA; Osterman JJ
Am J Obstet Gynecol; 1979 Jun; 134(3):315-20. PubMed ID: 377968
[TBL] [Abstract][Full Text] [Related]
24. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
25. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
26. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding.
Davis A; Godwin A; Lippman J; Olson W; Kafrissen M
Obstet Gynecol; 2000 Dec; 96(6):913-20. PubMed ID: 11084177
[TBL] [Abstract][Full Text] [Related]
27. Norgestimate: overview of a monophasic formulation.
Anderson FD; Gillmer MD
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
[No Abstract] [Full Text] [Related]
28. [Occurrence of bleeding in women using combined hormonal contraceptives (ethinylestradiol 35 micrograms/norgestimate 250 micrograms in relation to regularity of administration and cycle start day].
Paseková V; Chroust K
Ceska Gynekol; 2003 Mar; 68(2):84-8. PubMed ID: 12749175
[TBL] [Abstract][Full Text] [Related]
29. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
Hampton RM; Fisher AC; Pagano S; LaGuardia KD
Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
[TBL] [Abstract][Full Text] [Related]
30. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
31. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.
LaGuardia KD; Shangold G; Fisher A; Friedman A; Kafrissen M
Contraception; 2003 Jun; 67(6):431-7. PubMed ID: 12814811
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
[TBL] [Abstract][Full Text] [Related]
34. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German P; Moorehead L; Pang P; Vimal M; Mathias A
J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
[TBL] [Abstract][Full Text] [Related]
35. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
[TBL] [Abstract][Full Text] [Related]
37. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.
Kaunitz AM; Burkman RT; Fisher AC; LaGuardia KD
Obstet Gynecol; 2009 Dec; 114(6):1205-1212. PubMed ID: 19935020
[TBL] [Abstract][Full Text] [Related]
38. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
Creasy GW; Fisher AC; Hall N; Shangold GA
J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
[TBL] [Abstract][Full Text] [Related]
39. Supportive European data on a new oral contraceptive containing norgestimate.
Becker H
Acta Obstet Gynecol Scand Suppl; 1990; 152():33-9. PubMed ID: 2189283
[TBL] [Abstract][Full Text] [Related]
40. New progestogens in oral contraceptives.
Runnebaum B; Rabe T
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
